InfuSystems: More Upside Ahead

InfuSystems delivered a profit-focused turnaround with FY25 adjusted EBITDA up 24% while sustaining strong margins through GE contract restructuring. Wound Care revenue surged 154% and Oncology reached record volumes, alongside robust Patient Services growth. The balance sheet stays conservative (net debt 0.61x EBITDA, $55.2M liquidity) and share repurchases cut share count by 5% in H1, supporting a bullish outlook for earnings power.

Analysis

INFU’s setup is more interesting as an earnings-quality story than a revenue story. The market tends to underwrite microcap healthcare services on low-teens growth, but the combination of tighter contract economics, mix toward higher-margin care categories, and buybacks creates a path where EPS can compound materially faster than sales. That can drive multiple expansion if investors start treating it like a cash-generative niche service provider rather than a capital-constrained turnaround.

The main second-order effect is competitive: if INFU is using stronger margins and balance-sheet flexibility to defend pricing or partner more aggressively, smaller wound-care or infusion peers with weaker liquidity will be forced either to match economics or concede share. The GE restructuring also signals lower dependence on lower-return legacy arrangements, which should improve quality of revenue but can reduce headline top-line growth; that usually matters more to growth screens than to fundamental holders.

The risk is that the strongest growth engine may be reimbursement- and mix-driven rather than purely organic. That means the Wound Care step-up could normalize faster than consensus expects, especially if payer mixes or CMS rates move against them; the first real check will be the next 1-2 quarters of same-store volume and margin retention, not the annual adjusted EBITDA headline. Over 6-18 months, the thesis is falsified if EBITDA margin stalls, buybacks slow, or management has to reintroduce growth-at-all-cost behavior to protect revenue.

Contrarian view: this may still be under-owned because the stock has not been rewarded for capital allocation discipline. The bigger consensus miss is likely not that growth is fake, but that the market may be discounting the durability of the margin structure and the repurchase-driven EPS lift. If the current pace of cash deployment continues, the stock can rerate even with mid-single-digit revenue growth; if it doesn’t, the market will quickly reclassify it as a value trap.

Key Decisions for Investors

• Long INFU on pullbacks for a 3-6 month catalyst window; target a rerating tied to sustained margin expansion and continued buybacks, with downside invalidation if next-quarter EBITDA margin compresses or management trims guidance.
• Use INFU as a relative-value long versus a broader healthcare services proxy such as IHF for the next 1-3 months; thesis is that INFU’s capital returns and margin mix should outperform a basket still priced for slower EPS conversion.
• If options liquidity is adequate, buy a 3-6 month call spread on INFU rather than naked calls to express the rerating thesis with defined downside; this is only attractive if implied volatility remains below the expected move into the next earnings print.
• Set a hard watch item on reimbursement commentary and wound-care growth into the next two quarters; if the growth rate decelerates sharply from this base effect, reduce exposure before the market re-prices the story as non-recurring.
• For a higher-conviction entry, wait for confirmation that share repurchases remain active and net leverage stays below 1x EBITDA; that combination is the cleanest signal that EPS compounding can persist without balance-sheet risk.